Study guide
6.4 Tc-99m CNS, Infection, and Labeled Cells
Certified Nuclear Medicine Technologist CNMT
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current CNMT Exam Facts 1.2 How to Use This Guide
2 Radiation Physics Fundamentals
2.1 Radioactive Materials, Isotopes, and Decay Modes 2.2 Decay Calculations and Counting Statistics 2.3 Interactions of Radiation with Matter 2.4 Radiation Detector Types and Principles
3 Biological Effects & ALARA
3.1 Biological Effects of Radiation Exposure 3.2 ALARA and Protection Calculations 3.3 Dose Limits, Surveys, and Personal Monitoring
4 NRC & Regulatory Compliance
4.1 NRC Areas, Spills, Waste, and Records 4.2 Written Directives and DOT Shipping 4.3 EPA, OSHA, HIPAA, FDA, and USP Standards 4.4 Radioactive Waste Disposal and Regulatory Records
5 Generators & Kit Preparation
5.1 Radionuclide Generators and Quality Control 5.2 Radiopharmaceutical Kit Preparation 5.3 Radiopharmaceutical Quality Control
6 Tc-99m Diagnostic Agents
6.1 Tc-99m Cardiac Imaging Agents 6.2 Tc-99m Bone, Renal, and GU Agents 6.3 Tc-99m GI and Hepatobiliary Agents 6.4 Tc-99m CNS, Infection, and Labeled Cells
7 Non-Tc Diagnostic & PET Agents
7.1 Iodine and Indium Diagnostic Agents 7.2 Gallium, Thallium, Xenon, and Miscellaneous Agents 7.3 PET Radiopharmaceuticals 7.4 Neurologic, Breast, and Neuroendocrine PET Agents
8 Therapeutics, Adjuncts & Administration
8.1 Therapeutic Radiopharmaceuticals 8.2 Interventional and Adjunct Pharmaceuticals 8.3 Blood Labeling and Administration Techniques 8.4 Blockade, Comfort, and Gastrointestinal Adjunct Agents
9 Non-Imaging Instrumentation
9.1 Well Counters, Probes, and Survey Meters 9.2 Dose Calibrator Quality Control 9.3 Auxiliary and Patient Care Equipment
10 Imaging Systems & Quality Control
10.1 Gamma Camera Quality Control 10.2 SPECT and SPECT/CT Systems 10.3 PET and PET/CT Systems and QC 10.4 CT Systems, PACS, and Information Systems 10.5 CT Radiation Dose, Safety Alerts, and Protocol Optimization
11 Pulmonary, Bone, Oncology & Infection Imaging
11.1 Pulmonary Imaging Procedures 11.2 Bone and Musculoskeletal Imaging 11.3 Oncology Imaging Procedures 11.4 Infection Imaging Procedures
12 Renal, Endocrine & Hematopoietic Imaging
12.1 Renal and Genitourinary Imaging 12.2 Endocrine Imaging (Thyroid, Parathyroid, Adrenal) 12.3 Hematopoietic and Bone Marrow Imaging 12.4 Thyroid Uptake Measurement and Radioiodine Survey Technique
13 Cardiovascular Procedures
13.1 Myocardial Perfusion Imaging 13.2 Cardiac Function, Viability, and Special Studies 13.3 Exercise and Pharmacologic Stress Testing
14 GI, CNS, Therapy & Hybrid CT Procedures
14.1 Gastrointestinal Procedures 14.2 Central Nervous System Procedures 14.3 Radionuclide Therapy Procedures 14.4 CT and Hybrid Imaging in Nuclear Medicine 14.5 CSF Studies: Cisternography, Leak Localization, and Shunt Patency
15 Patient Care & Clinical Workflow
15.1 Patient Care, Education, and Consent 15.2 Scheduling and Radiopharmaceutical Procurement 15.3 Acquisition, Positioning, and Image Quality 15.4 Image Processing and Quantitative Analysis 15.5 Non-Imaging Studies: Specimens, Counting, and Error Analysis
6.4 Tc-99m CNS, Infection, and Labeled Cells
Key Takeaways Explain This Topic AI
Tc-99m HMPAO (Ceretec®) and ECD (Neurolite®) are lipophilic brain perfusion agents that cross the blood–brain barrier and are retained in proportion to regional cerebral blood flow
HMPAO can also label leukocytes for infection/inflammation imaging; labeling quality, viability, and same-patient reinjection are critical
Tc-99m MAA particles trap in pulmonary arterioles for perfusion imaging; adult particle number is limited (commonly keep roughly 200,000–700,000 particles; reduce in pulmonary hypertension/right-to-left shunt risk)
Tc-99m tilmanocept (Lymphoseek®) binds mannose receptors (CD206) on reticuloendothelial cells for sentinel node mapping
Brain agents require quiet/dark controlled conditions for some protocols; infection WBC studies need careful handling of blood products and correlation with clinical site
Last updated: August 2026
6.4 Tc-99m CNS, Infection, and Labeled Cells
Quick Answer: HMPAO/ECD → lipophilic rCBF brain agents retained after BBB crossing. HMPAO-WBC → labeled leukocytes for infection. MAA → mechanical capillary blockade in lung (watch particle count ). Tilmanocept (Lymphoseek®) → CD206 mannose-receptor binding for sentinel nodes. Cell labeling and particle limits are high-stakes safety topics.
- Brain Perfusion: HMPAO and ECD
- Mechanism
Tc-99m exametazime (HMPAO, Ceretec®) and Tc-99m bicisate (ECD, Neurolite®) are small lipophilic molecules that cross the intact blood–brain barrier . Inside the brain they convert to more hydrophilic species and are retained in proportion to regional cerebral blood flow (rCBF) at injection. Imaging thus maps perfusion patterns—not a specific “Alzheimer tracer” chemistry like amyloid PET, though patterns can support dementia workups and other neurologic indications.
- Feature Tc-99m HMPAO (Ceretec®) Tc-99m ECD (Neurolite®)
- Mechanism Lipophilic → BBB → trapped after conversion Similar lipophilic rCBF agent
- Stability Fresh preparation / stabilizer rules important Generally more stable post-reconstitution
- Excretion emphasis More background soft tissue possible Often cleaner soft-tissue clearance
- Admin IV IV
- Typical adult dose ~15–30 mCi (555–1110 MBq) range Similar order (~15–30 mCi)
- Indications and Prep
Clinical uses include stroke and other cerebrovascular perfusion patterns, dementia pattern support (e.g., temporoparietal decreases in Alzheimer-type patterns versus more frontal patterns in some frontotemporal cases—always interpret with neurology), epilepsy (ictal vs interictal injections— timing is everything ), and brain-death adjunct imaging (absent intracranial uptake with proper technique and quality control). Inject IV in a quiet, low-stimulation environment; keep interaction minimal so cognitive or sensory activation does not create artifactual focal cortical “hot spots.” Keep eyes open/closed consistent with the lab protocol. Image typically 30–90 minutes after injection. Traps: injecting hours-old unstable HMPAO, patient talking or reading during uptake, and mistaking scalp or sinus activity for cortex.
- Infection Imaging: HMPAO-Labeled Leukocytes
- Mechanism
Autologous white blood cells labeled with Tc-99m HMPAO migrate to sites of infection/inflammation. This is a cell trafficking mechanism—not simple free-tracer leakage. In-111 oxine WBCs are an alternative (longer half-life, dual-isotope with sulfur colloid for marrow)—Domain III expects you to know Tc-99m HMPAO is a common Tc label for WBCs.
Critical Labeling Quality Steps
Positive patient identification and a dedicated blood-labeling workflow.
Adequate blood volume with proper sedimentation/separation to harvest leukocytes.
Correct HMPAO kit preparation and timed incubation with cells.
Washing steps to remove unbound technetium.
Assay labeling efficiency ; inspect for clumping or damaged cells.
Reinject promptly only into the donor patient (never another patient).
Typical administered activity is often ~5–10+ mCi of labeled cells (lab-dependent). Image at about 1–4 hours and sometimes at ~24 hours depending on body region. Indications include osteomyelitis, infected prostheses (often paired with marrow mapping), abdominal abscess, inflammatory bowel disease, and fever of unknown origin. Sterile inflammation, drains, and recent surgery can false-positive; poor viability or chronic low-grade infection can false-negative. Free Tc or damaged cells distort liver, spleen, and lung patterns.
- Lung Perfusion: Tc-99m MAA
- Mechanism
Tc-99m macroaggregated albumin (MAA) particles (typically 10–90 µm ) lodge mechanically in pulmonary arterioles/capillaries — capillary blockade . Distribution maps regional pulmonary arterial perfusion . Combined with ventilation (Xe-133, Tc-99m DTPA aerosol, or Technegas where available) for PE workup (V/Q).
Particle Limits and Safety
Parameter Entry-level teaching points
Adult particle number Commonly ~200,000–700,000 particles per dose (lab/package ranges; know the concept of an upper limit)
Why limit? Each particle occludes a tiny vessel; excess particles risk hypoxia in fragile patients
Reduce particles Pulmonary hypertension, known right-to-left shunt, pneumonectomy, infants/children (weight-based)
Adult activity Often ~1–4 mCi (37–148 MBq) for perfusion
Injection technique Supine preferred; no blood withdrawn into syringe (clots → hot spots); agitate gently; avoid free-Tc
Right-to-left shunt: particles enter systemic circulation → brain/kidney visualization. May be diagnostic but requires reduced particle load when shunt is known/suspected.
Hot spots on perfusion images: clumped MAA or blood clots in syringe—technical, not PE.
- Lymphoscintigraphy: Tilmanocept (Lymphoseek®)
- Mechanism
Tc-99m tilmanocept is a CD206 mannose receptor –targeted agent. It binds RES cells in lymph nodes, designed for rapid clearance from injection site and persistent node retention—used for sentinel lymph node mapping (breast, melanoma, and other approved/protocol uses).
Unlike filtered sulfur colloid , which depends mainly on particle size and phagocytosis, tilmanocept uses specific receptor binding . Injection routes are intradermal, subcutaneous, or peritumoral/periareolar per surgical protocol—not an IV liver-spleen dose. Administered activity is in a low mCi range per package insert; map drainage with a gamma camera and localize nodes with an intraoperative probe. Traps include skin contamination mistaken for nodes, wrong injection depth, and failure to image all relevant drainage basins (for example, internal mammary or epitrochlear pathways when clinically relevant).
Master Comparison Table
- Agent Mechanism Classic indication Critical prep / QC
- HMPAO / ECD Lipophilic rCBF + BBB retention Brain perfusion SPECT Quiet uptake; stable kit
- HMPAO-WBC Leukocyte migration Infection/inflammation Labeling efficiency; same-patient reinjection
- MAA Arteriolar particle trapping Lung perfusion / V/Q Particle limits; no syringe clots
- Tilmanocept CD206 receptor binding Sentinel node mapping Correct interstitial technique
PE perfusion → MAA . Osteomyelitis cells → WBC labeling QC . Sentinel receptor agent → tilmanocept . Particle limits and blood-label identity are non-negotiable safety checks.